- GLOPERBA® (colchicine) oral solution. Prescribing Information. SCILEX Pharmaceuticals; March 2024.
- Robinson PC, Terkeltaub R, Pillinger MH, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025 Epub 2021 Aug 18.
- Data on file. SCILEX Pharmaceuticals; March 2024.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180 Epub 2020 May 11.
- Kim HW, Joo YS, Yun HR, et al. Colchicine use and the risk of CKD progression: a multicentre nested case-control study. Rheumatology (Oxford). 2022;61(11):4314-4323. doi:10.1093/rheumatology/keac077
- Khanna D, Khanna PP, FitzGerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461. doi: 10.1002/acr.21773
- Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432.
- Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845-855. doi: 10.1007/s40261-014-0238-6
- Rahimi M, Alizadeh R, Hassanian-Moghaddam H, Zamani N, Kargar A, Shadnia S. Clinical manifestations and outcomes of colchicine poisoning cases; a cross sectional study. Arch Acad Emerg Med. 2020;8(1):e53. PMID: 32440664
- Data on file. SCILEX Pharmaceuticals; March 2024.
- Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006 Dec;73(6):672-678. doi: 10.1016/j.jbspin.2006.03.006.
- Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432.
- Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal tract disorders in older age. Can J Gastroenterol Hepatol. 2019 Jan;2019:6757524. doi: 10.1155/2019/6757524
- Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011;9(5):271-285. doi: 10.1016/j.amjopharm.2011.07.004 Epub 2011 Aug 17.
- Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006 Dec;73(6):672-678. doi: 10.1016/j.jbspin.2006.03.006
- Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013 May 20;7:419-434. doi: 10.2147/PPA.S44646
- COLCRYS (colchicine, USP) tablets. Prescribing Information. Takeda Pharmaceuticals America, Inc.; November 2012.
- Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461-470.
- Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatol Ther. 2021 Mar;8(1):183-197. doi: 10.1007/s40744-020-00260-1
- Chaudhri K, Kearney M, Di Tanna GL, Day RO, Rodgers A, Atkins ER. Does splitting a tablet obtain the accurate dose?: A systematic review protocol. Medicine (Baltimore). 2019 Oct;98(42):e17189. doi: 10.1097/MD.0000000000017189
- GLOPERBA medication guide. SCILEX, LLC; 2019.
IMPORTANT SAFETY INFORMATION
Important Safety Information for GLOPERBA® (colchicine)
- Colchicine 0.6 mg oral solution is contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given GLOPERBA.
- Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.
- Blood dyscrasias, such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia, have been reported with colchicine used in therapeutic doses.
- Drug interactions: Concomitant use of GLOPERBA with inhibitors of both CYP3A4 and P-gp should be avoided. If treatment with colchicine is necessary, a reduced daily dose should be considered and the patient should be closely monitored for colchicine toxicity and, if present, consider lowering the dose, temporary interruption, or discontinuation of colchicine.
- Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider lowering the dose, temporary interruption, or discontinuation of GLOPERBA.
- The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.
Indication
GLOPERBA 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.
GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.
You are encouraged to report negative side effects of prescription drugs to the FDA.
To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for GLOPERBA.